IL-3 belongs to the family of hematopoietic cytokines including GM-CSF and IL-5. For many years IL-3 was considered to be mainly involved in hematopoiesis and defense against parasites. We have identified IL-3 as an essential cytokine in systemic lupus erythematodes (SLE), rheumatoid arthritis and multiple sclerosis and demonstrate that T cells are the main source of IL-3 in murine models of inflammation. Blockade of IL-3 with an antibody or genetic deletion of IL-3 markedly improved disease activity in mouse models for systemic lupus (MRL-lpr), rheumatoid arthritis (collagen-induced arthritis, CIA) and multiple sclerosis (experimental autoimmune encephalitis, EAE). We and others found that IL-3 is an essential inductor cytokine for several classical proinflammatory cytokines, like IL-6, TNF-alpha and IL-1. In addition, IL-3 is essential for mobilization of innate immune cells from the bone marrow during inflammation. Thus, blockade of IL-3 interferes with multiple proinflammatory mechanisms explaining the superior efficacy of inhibitory IL-3 antibodies. Blockade or deficiency of IL-3 is very well tolerated in mice. In contrast, injection of recombinant IL-3 significantly increased disease activity in mouse models and induced polyarthritis in healthy rhesus monkeys.
In humans, IL-3 activates plasmocytoid dendritic cells (pDC), monocytes, basophils, mast cells, B cells and endothelial cells. Plasmacytoid dendritic cells are the most important producers of type I interferons that play a central role in the pathogenesis of systemic lupus. Also monocytes and B cells importantly contribute to autoimmune diseases in humans. In endothelial cells IL-3 induces the upregulation of E- and P-selectins and thus enables the transendothelial migration of leukocytes. We have generated multiple monoclonal antibodies against human IL-3 and currently analyze the expression of IL-3 in patients with autoimmune and inflammatory diseases. We also evaluate the potential of these antibodies for treatment of patients.